Review Article

Hemophilia A: Strategies for Improving Long-Term Holistic Management, Adherence, and Quality of Life

Miguel A. Escobar,(1) MD, Cindy Leissinger,(2) MD, and Guy Young,(3) MD

From (1)University of Texas Health Science Center and Gulf States Hemophilia & Thrombophilia Center, Houston, Texas; (2)Louisiana Center for Bleeding and Clotting Disorders New Orleans, Louisiana; (3)Hemostasis & Thrombosis Center, Children’s Hospital Los Angeles, and University of Southern California, Keck School of Medicine, Los Angeles, California

Authors’ disclosures of conflicts of interest are found at the end of this article.


J Adv Pract Oncol 2022;13(Suppl 3):7–19 | https://doi.org/10.6004/jadpro.2022.13.4.8 | © 2022 Harborside™


  

ABSTRACT

Hemophilia A is a rare inherited bleeding disorder characterized by a deficiency in factor VIII. The evolution of currently approved prophylaxis therapy in hemophilia A will be reviewed, including the clinical value of prophylaxis, real-world experience with prophylaxis, and patient quality-of-life factors that must be considered when choosing treatment options for these patients.




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.